clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03418324 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
P582 | end time | 2020-01-01 | |
P921 | main subject | metastatic prostate carcinoma | Q55779807 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 40 | |
P6153 | research site | Cedars-Sinai Medical Center | Q1052562 |
P859 | sponsor | Cedars-Sinai Medical Center | Q1052562 |
P580 | start time | 2018-03-05 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy |
Search more.